(Sensei) Conditionally active CD28xVISTA bispecific antibodies induce myeloid-driven tumor-specific T-cell co-stimulation for improved cancer immunotherapy

CD28xVISTA bispecific antibodies in immunotherapy

April 9, 2024


Tumor-specific recruitment of co-stimulatory bispecific antibodies (bsAbs) is emerging as a promising therapeutic strategy. We developed pH-selective CD28xVISTA bsAbs to act within the acidic tumor microenvironment (TME).These bsAbs are designed for selective tripartite “trans-activation” of CD28 in theTME, aiming for enhanced T-cell-mediated cancer cell killing while minimizing systemic T-cell activation and Cytokine Release Syndrome (CRS) risk.The trans-activation mechanism relies on engagement of VISTA on myeloid cells, where this immune checkpoint acts to suppress T-cell activation in the low pH environment (~pH 6) found in many tumors1. We (Sensei) and others previously developed pH-selective monoclonal antibodies (mAbs) to inhibit this checkpoint1,2. Here we exploit these findings to develop CD28xVISTA bsAbs for tumor-targeted CD28 agonism and T-cell co-stimulation.

Related products

Catalogue product


The hCD28 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD28 in fully immunocompetent mice.

Customized product

No items found.